Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Gets Remaining Compounds for ToxCast Screening

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today said that it has received the remaining balance of the compound library from the Environmental Protection Agency's Phase II ToxCast screening program.

As a result, the firm said that it expects its revenue to come in at the top end of its guidance for the fourth quarter and full-year 2010.

Caliper has been participating in the ToxCast program since 2007. The Hopkinton, Mass.-based firm's Caliper Discovery Alliances and Services business has been applying its predictive toxicity panel to screen the compounds provided by EPA.

The first phase of the ToxCast program included 300 compounds, and the second phase included a total 700 compounds. The balance from the phase II program (phase IIb) announced last week by EPA included 350 compounds.

"Receiving this most recent compound set will allow our scientists to complete Phase IIb compound screening over the next several months, and will likely push Caliper's revenue to the top end of our corporate revenue guidance range for the fourth quarter and full year," Caliper President and CEO Kevin Hrusovsky said in a statement.

After reporting its third-quarter financials in late October, Caliper increased its revenue guidance for fiscal-year 2010 to between $119 million and $121 million, up from previous guidance of between $117 million and $120 million.

This past summer, Caliper said that its backlog of ToxCast phase II task orders was $4.7 million.